<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01684982</url>
  </required_header>
  <id_info>
    <org_study_id>DiLOR_2012</org_study_id>
    <nct_id>NCT01684982</nct_id>
  </id_info>
  <brief_title>Everolimus Stent in Myocardial Infarction</brief_title>
  <acronym>RaCES-MI</acronym>
  <official_title>Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With ST Elevation Myocardial Infarction (STEMI) (RaCES-MI Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Giuseppe Moscati Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Giuseppe Moscati Hospital</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized trial to test the efficacy and safety of newer Drug Eluting Stent generation in
      patient with acute myocardial infarction treated with primary percutaneous coronary
      intervention (PCI)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety of drug-eluting stents (DES) in the treatment of coronary artery
      disease is well established. It is well known that Drug Eluting Stent (DES) have
      dramatically decreased Restenosis rates for both on-label and off-label indications.
      However, the concern for increased (late) stent thrombosis is still present DES implantation
      in patient with acute myocardial infarction is still controversial because acute coronary
      lesion presents the highest possible thrombotic burden Newer DES with new antiproliferative
      drugs and more biocompatible polymers have shown a significant reduction of (late) stent
      thrombosis in patients in stable condition.

      Aim of the study was to asses the long term efficacy and safety on second generation
      everolimus eluting stent compared with first generation sirolimus eluting stent
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>cardiac death, reinfarction and Target Vessel Revascularization (TVR)</measure>
    <time_frame>36 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any death of cardiac origin, any myocardial infarction and any new revascularization of the infarct related artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac death, reinfarction, Target Vessel Revascularization (TVR) and definite/probable stent thrombosis</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>everolimus eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>second generation drug eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sirolimus eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first generation drug eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everolimus eluting stent</intervention_name>
    <description>experimental arm of a comparison between drug eluting stents</description>
    <arm_group_label>everolimus eluting stent</arm_group_label>
    <other_name>XIENCE V Abbott Vascular</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus eluting stent</intervention_name>
    <description>control arm of a comparison between drug eluting stents</description>
    <arm_group_label>sirolimus eluting stent</arm_group_label>
    <other_name>CYPHER Johnson &amp; Johnson</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All ST segment elevation myocardial infarction (STEMI) patients eligible for primary
             PCI

        Exclusion Criteria:

          1. Contraindication to dual antiplatelet therapy for 12 months

          2. Known allergy to sirolimus or everolimus

          3. Major surgical procedure planned within 1 month.

          4. History, symptoms, or findings suggestive of aortic dissection.

          5. Participation in other trials

          6. Pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIO DI LORENZO, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO MOSCATI AVELLINO ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ROSARIO SAURO, MD</last_name>
    <role>Study Director</role>
    <affiliation>AO MOSCATI AVELLINO ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology AO Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW; Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. Review.</citation>
    <PMID>22529227</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo E, Carbone G, Sauro L, Casafina A, Capasso M, Sauro R. Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome. Curr Cardiol Rep. 2011 Oct;13(5):459-64. doi: 10.1007/s11886-011-0207-0. Review.</citation>
    <PMID>21792636</PMID>
  </reference>
  <reference>
    <citation>Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schömig A, Kastrati A. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol. 2010 Jun;99(6):345-57. doi: 10.1007/s00392-010-0133-y. Epub 2010 Mar 11.</citation>
    <PMID>20221617</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50.</citation>
    <PMID>19781402</PMID>
  </reference>
  <reference>
    <citation>Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Queré M, de Vries CJ, van Boven AJ. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2012 Jul 31;60(5):381-7. doi: 10.1016/j.jacc.2012.01.073.</citation>
    <PMID>22835668</PMID>
  </reference>
  <reference>
    <citation>Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012 Aug 31. [Epub ahead of print]</citation>
    <PMID>22951305</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 1, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Giuseppe Moscati Hospital</investigator_affiliation>
    <investigator_full_name>Emilio Di Lorenzo MD PhD</investigator_full_name>
    <investigator_title>Chief Interventional Cardiology</investigator_title>
  </responsible_party>
  <keyword>Primary PCI</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
